Difference between revisions of "Asparaginase Erwinia chrysanthemi (Erwinaze)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
==General information== | ==General information== | ||
| Line 17: | Line 16: | ||
*[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]</ref> | ||
| + | ==History of changes in FDA indication== | ||
| + | * 11/18/2011: Initial FDA approval "as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with [[Acute lymphocytic leukemia | acute lymphoblastic leukemia (ALL)]] who have developed hypersensitivity to [[Asparaginase (Elspar) | E. coli-derived asparaginase]]. | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| Line 24: | Line 26: | ||
[[Category:Enzymes]] | [[Category:Enzymes]] | ||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2011]] | ||
Revision as of 02:04, 6 November 2014
General information
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2][3]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Asparaginase patient drug information (Chemocare) — this is for Asparaginase (Elspar), not Erwinaze[4]
- Brief patient counseling information can be found on the bottom of page 2 of the package insert[1]
- Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/18/2011: Initial FDA approval "as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
References
- ↑ 1.0 1.1 1.2 Asparaginase Erwinia chrysanthemi (Erwinaze) package insert
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)
- ↑ Erwinaze manufacturer's website
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)